drugset / Trial / NCT03738878
Mechanism(s) Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 1
RandomizedCrossoverQuadruple-blindBasic science
Summary
The purpose of this study is to test the hypothesis that combined angiotensin receptor blockade (ARB)/neprilysin (NEP) inhibition potentiates the effects of exogenous bradykinin, substance P, and brain natriuretic peptide (BNP) on forearm blood flow or endothelial tissue-type plasminogen activator (t-PA) release compared to ARB alone. A secondary goal is to determine if there is an interactive effect of ARB/NEP inhibition and dipeptidyl peptidase 4 (DPP4) inhibition on responses to these peptides.
Timeline
- Start
- 2018-11-15
- Primary completion
- 2024-12-01
- Completion
- 2024-12-01
Outcome
Outcome not reported
Stopped: “An alternative study was developed to replace this study.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | LCZ696 | Unknown | 200 unknown | Oral |
| Comparator | Sitagliptin | Small molecule | 200 mg | Oral |
| Comparator | Valsartan | Unknown | 160 mg | Oral |
| Comparator | BNP | Unknown | — | Other |
| Comparator | Bradykinin | Protein / enzyme biologic | — | Other |
| Comparator | Substance P | Small molecule | — | Other |